|
Q-1452
|
Monday, September 21, 2026 |
With regard to community mailboxes being procured in connection with Canada Post's planned conversion of approximately four million addresses from door-to-door delivery: (a) what are the details of each contract and agreement currently being used to supply community mailboxes, including the (i) supplier, (ii) manufacturer, if different from the supplier, (iii) country where the mailboxes are manufactured, (iv) contract value, (v) contract period, (vi) number of mailboxes to be supplied, (vii) procurement method, (viii) number of bids received; (b) for each agreement in (a), (i) when was it originally awarded, (ii) has it been renewed, extended or amended since December 16, 2025, and, if so, on what dates and for what values, (iii) was the successful bid the lowest-priced bid and, if not, what was the difference between the successful bid and the lowest-priced bid; and (c) regarding Canada Post's statement that it is subject to a government of Canada directive requiring alignment with the Buy Canadian Procurement Policy, (i) what is the name and date of the directive, (ii) when did it become applicable to Canada Post, (iii) what requirements does it impose on the procurement of community mailboxes, (iv) were those requirements applied to each agreement in (a), and, if not, why not? |
Awaiting response |
Friday, November 6, 2026 |
|
Q-1451
|
Monday, September 21, 2026 |
With regard to Health Canada inspections of Grifols plasma collection facilities in Canada, since January 1, 2022: (a) what are the details of each inspection, including the (i) facility and location, (ii) date of the inspection, (iii) compliance rating, (iv) number of deficiencies identified; (b) for each inspection where deficiencies were identified, what (i) were the deficiencies, (ii) was the date Grifols was notified, (iii) corrective actions were proposed by Grifols, (iv) is status of those corrective actions; (c) for each inspection that resulted in a non-compliant rating, what actions, if any, did Health Canada take beyond identifying the non-compliance and requiring corrective action, including any (i) additional conditions or restrictions imposed on the facility, (ii) follow-up inspection, (iii) suspension or restriction of plasma collection, (iv) other compliance or enforcement action; (d) which Grifols plasma collection facilities have not been inspected by Health Canada during this period, including the date of their most recent inspection, if applicable; and (e) since January 1, 2022, what are the details of each meeting between the Minister of Health or members of the minister's office and Grifols Canada, Grifols S.A., or any representatives of either company, including the (i) date, (ii) location or method of the meeting, (iii) subject or purpose of the meeting, (iv) names and titles of all individuals in attendance? |
Awaiting response |
Friday, November 6, 2026 |
|
Q-1450
|
Monday, September 21, 2026 |
With regard to contracts awarded under the Buy Canadian Procurement Policy Framework since December 16, 2025: (a) for each contract, what is the (i) date, (ii) value, (iii) vendor, (iv) description of the goods or services provided, (v) contract number, (vi) department or agency, (vii) procurement method, (viii) country of ultimate ownership or control of the vendor, if known, (ix) percentage of Canadian value-added committed by the vendor, (x) Canadian supplier preference or Canadian-content measures applied; (b) what is the total number and value of contracts awarded to (i) Canadian-controlled suppliers, (ii) foreign-controlled suppliers; (c) in how many procurements did the application of Canadian supplier or Canadian-content preferences change the ranking of bids; and (d) how many supplier attestations have been verified following contract award and what were the results? |
Awaiting response |
Friday, November 6, 2026 |
|
Q-1449
|
Monday, September 21, 2026 |
With regard to contracts awarded under the Procurement Strategy for Indigenous Business since April 1, 2021, broken down by fiscal year and federal department or agency: (a) what are the details of each contract awarded, including the (i) date, (ii) value, (iii) vendor, (iv) description of the goods or services provided, (v) contract number, (vi) department or agency; (b) how many contracts valued at $2 million or more required a mandatory pre-award audit, including their total value; (c) of the contracts in (b), how many had a pre-award audit (i) requested, (ii) completed prior to contract award, (iii) not completed prior to contract award; (d) for each contract in (c)(iii), what was the (i) date, (ii) value, (iii) vendor, (iv) description of the goods or services provided, (v) contract number, (vi) department or agency, (vii) reason the contract was awarded without a completed pre-award audit; (e) how many post-award or discretionary audits were (i) requested, (ii) completed; (f) how many audits identified non-compliance with Indigenous ownership, control or content requirements, including the total value of the associated contracts; (g) as a result of the non-compliance in (f), how many contracts resulted in (i) termination, (ii) recovery or withholding of funds, (iii) removal of a business from the Indigenous Business Directory, (iv) disqualification from future set-aside procurements, (v) referral to law enforcement; and (h) what are the details of each contract in (g), including the (i) date, (ii) value, (iii) vendor, (iv) description of the goods or services provided, (v) contract number, (vi) department or agency, (vii) reason of non-compliance? |
Awaiting response |
Friday, November 6, 2026 |
|
Q-1398
|
Wednesday, June 17, 2026 |
With regard to foreign nationals holding a work permit under the foreign medical resident C45 stream of the International Mobility Program, broken down by calendar year from 2016 and further broken down by country of citizenship: (a) what is the total number of unique individuals who held a valid work permit under Labour Market Impact Assessment exemption code C45, as of December 31 of each year; (b) what is the total number of new work permits issued under the C45 stream during each calendar year; (c) what is the total number of work permits under the C45 stream that expired or reached their specified end-date during each calendar year; (d) of the expired work permits in (c), (i) how many individuals departed Canada following permit expiry, (ii) how many individuals remained in Canada under a valid temporary status; (e) what is the total number of individuals who held a work permit under the C45 stream and subsequently submitted an asylum or refugee claim in Canada; (f) what is the total number of individuals who held a work permit under the C45 stream and subsequently transitioned to another immigration status, broken down by specific pathway obtained, including permanent residence (via Express Entry, Provincial Nominee Programs, or humanitarian streams), unrestricted open work permits, and employer-specific work permits outside the C45 stream; (g) of the individuals in (a), what is the total number identified via the Employer Portal or application materials as internationally sponsored medical trainees whose training was funded by a foreign government; (h) with specific regard to citizens of Saudi Arabia, what is the total number who held a valid C45 work permit as of December 31 of each calendar year; (i) what is the distribution of the valid C45 work permits in (a), broken down by (i) host Canadian province or territory, (ii) the specific university Postgraduate Medical Education office listed as the employer; (j) what is the breakdown of the C45 work permits in (a) by National Occupational Classification code, specifically differentiating between specialists in clinical medicine, surgical specialists, and general practitioners or family physicians; (k) what is the total number of spouse open work permits and dependent study permits issued concurrently or subsequently to the family members of the C45 work permit holders in (a); and (l) what is the total number of employer compliance inspections conducted by Immigration, Refugees and Citizenship Canada on Canadian medical schools or hospitals hosting C45 permit holders, and how many (i) monetary penalties, (ii) non-compliance warnings, were issued? |
Answered |
Monday, September 21, 2026 |
|
Q-1384
|
Wednesday, June 17, 2026 |
With regard to Health Canada's Special Access Program, since 2016, and broken down by calendar year: (a) how many applications for psilocybin were (i) received, (ii) approved, (iii) denied; (b) how many applications for diacetylmorphine were (i) received, (ii) approved, (iii) denied; and (c) how many requests for benzoylmethylecgonine were (i) received, (ii) approved, (iii) denied? |
Answered |
Monday, September 21, 2026 |
|
Q-1383
|
Wednesday, June 17, 2026 |
With regard to findings of medical inadmissibility under section 38(1) of the Immigration and Refugee Protection Act, broken down by year since 2015: (a) what is the number of applicants who received a Procedural Fairness Letter citing a concern of medical inadmissibility, broken down by (i) ground of inadmissibility (danger to public health, danger to public safety, or excessive demand on health or social services), (ii) immigration stream (economic class, family class, temporary resident, or other); (b) of the applicants in (a), what is the number of applicants ultimately found inadmissible following that process, broken down by (i) ground of inadmissibility, (ii) immigration stream; (c) of the applicants in (a) who were ultimately found admissible, what is the number for each, broken down by (i) ground of inadmissibility, (ii) immigration stream, (iii) basis for that outcome (mitigation plan accepted, updated medical evidence, or other); (d) what was the excessive demand cost threshold applied in each year, including the (i) annual figure, (ii) five-year cumulative figure; and (e) how many applicants were exempted from an excessive demand assessment under the categories set out in section 38(2) of the Act, broken down by exemption category (protected persons, refugees, sponsored spouses or common-law partners, or dependent children)? |
Answered |
Monday, September 21, 2026 |
|
Q-1381
|
Wednesday, June 17, 2026 |
With regard to federal funding for human immunodeficiency virus research and programming since 2016: (a) what is the total amount of human immunodeficiency virus-related funding provided by the Canadian Institutes of Health Research for research, broken down by year; (b) what are the details of each Canadian Institutes of Health Research grant in (a) that involved the development, evaluation, or piloting of a specific human immunodeficiency virus prevention, testing, treatment, harm reduction, or service delivery program or intervention, including, for each, the (i) recipient, (ii) year, (iii) amount, (iv) program or intervention studied, (v) stated objective of the research; (c) for each program or intervention in (b), what funding has any federal department or agency provided to implement or deliver that program or intervention, including the (i) department or agency, (ii) name of the funding program, (iii) recipient, (iv) amount, (v) start and end dates; (d) for each program or intervention in (b) with no funding in (c), what was the reason implementation funding was not provided; and (e) what mechanism, if any, exists within the federal government to assess Canadian Institutes of Health Research-funded human immunodeficiency virus research for potential implementation funding once the research concludes? |
Answered |
Monday, September 21, 2026 |
